Menu
Not yet recruiting NCT06626932

Implications of Biological and Procedural Factors of 18-f FDG Uptake by Normal Organs and Neoplastic Lesions

Observational Oncologic Diseases

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: 18 FDG (Fludeoxyglucose 18F).
Who it may be relevant to
Registry conditions: Oncologic Diseases. Basic parameters: 1 year — 90 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Implications of Biological and Procedural Factors of 18-f FDG PET/CT Uptake by Normal Organs and Neoplastic Lesions

Overview

To evaluate implications of biological and procedural factors of 18-f FDG PET/CT uptake on normal organs and neoplastic lesions.

Detailed description

18-f FDG is used on oncological patients undergoing PET/CT study at our nuclear medicine unit , its uptake by the tissues depends on glucose blood level and consumption then we evaluate the implications of biological and procedural factors on the uptake by normal organs and neoplastic lesions using standardized uptake values SUVmax , mean and peak.

Interventions

  • Radiation 18 FDG (Fludeoxyglucose 18F)
    18-f FDG

Primary outcome measures

  • PET/CT scan on cancer patient will be performed to evaluate the biological and procedural factors of 18-f FDG uptake by multiple normal organs and neoplastic lesions using Standardized uptake values [Time frame: 2 years]

Eligibility criteria

Inclusion criteria

  • cancer patients referred to nuclear medicine unit

Exclusion criteria

  • patients with increased FDG uptake associated with non malignant causes such as diffuse bone marrow FDG uptake or lung infection or patients with extensive metastasis in target organs

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Egypt · 1 center
  • Faculty of Medicine — Asyut

Identifiers

NCT: NCT06626932 · 18-FDG PET/CT scan

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗